NASDAQ:GBTGlobal Blood Therapeutics Stock Price, Forecast & News

Global Blood Therapeutics' stock was trading at $54.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GBT shares have increased by 25.2% and is now trading at $68.67. View which stocks have been most impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Global Blood Therapeutics.

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Global Blood Therapeutics.

Global Blood Therapeutics Inc (NASDAQ:GBT) issued its quarterly earnings results on Wednesday, May, 6th. The company reported ($1.20) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($1.47) by $0.27. The business had revenue of $14.12 million for the quarter, compared to analysts' expectations of $3.65 million. During the same period in the prior year, the company earned ($0.87) earnings per share. View Global Blood Therapeutics' earnings history.

16 brokerages have issued 1-year price objectives for Global Blood Therapeutics' stock. Their forecasts range from $60.00 to $150.00. On average, they expect Global Blood Therapeutics' stock price to reach $105.13 in the next year. This suggests a possible upside of 53.1% from the stock's current price. View analysts' price targets for Global Blood Therapeutics.

News stories about GBT stock have trended very positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Global Blood Therapeutics earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutGlobal Blood Therapeutics.

Global Blood Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 9,450,000 shares, a decline of 6.4% from the April 30th total of 10,100,000 shares. Based on an average trading volume of 972,400 shares, the days-to-cover ratio is presently 9.7 days. Currently, 15.9% of the shares of the company are short sold. View Global Blood Therapeutics' Current Options Chain.

Some companies that are related to Global Blood Therapeutics include Alnylam Pharmaceuticals (ALNY), Merck KGaA (MKGAF), Teva Pharmaceutical Industries (TEVA), GALAPAGOS NV/S (GLPG), GRIFOLS S A/S (GRFS), Beigene (BGNE), Catalent (CTLT), Sarepta Therapeutics (SRPT), Horizon Therapeutics (HZNP), Dr.Reddy's Laboratories (RDY), Mylan (MYL), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), TherapeuticsMD (TXMD), Exelixis (EXEL), AbbVie (ABBV), Advanced Micro Devices (AMD), Square (SQ) and Vertex Pharmaceuticals (VRTX).

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.95%), BlackRock Inc. (7.84%), Janus Henderson Group PLC (7.47%), Wellington Management Group LLP (4.54%), State Street Corp (3.59%) and Capital World Investors (2.38%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown. View institutional ownership trends for Global Blood Therapeutics.

GBT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Wellington Management Group LLP, Franklin Resources Inc., Frontier Capital Management Co. LLC, BlackRock Inc., Two Sigma Advisers LP, Fernwood Investment Management LLC, and Wells Fargo & Company MN. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Ted W Love, and Tricia Borga Suvari. View insider buying and selling activity for Global Blood Therapeutics.

GBT stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Capital World Investors, TimesSquare Capital Management LLC, Peregrine Capital Management LLC, Perceptive Advisors LLC, JPMorgan Chase & Co., Morgan Stanley, and Morgan Stanley. View insider buying and selling activity for Global Blood Therapeutics.

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GBT stock can currently be purchased for approximately $68.67.

Global Blood Therapeutics has a market capitalization of $4.18 billion and generates $2.11 million in revenue each year. The company earns $-266,770,000.00 in net income (profit) each year or ($4.71) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.

The official website for Global Blood Therapeutics is www.gbt.com.

Global Blood Therapeutics' mailing address is 181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]